ArticlePloS one2013
Investigating the antiproliferative activity of high affinity DNA aptamer on cancer cells.
Article in PloS one, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 41 citations in OpenAlex.
- Gold Nanoprism Enhanced SERS Aptasensor for Simultaneous Detection of Thrombin and VEGF.Sensors and actuators. B, Chemical · 2025Article
- Protective Effects of Collagen Tripeptides in Human Aortic Endothelial Cells by Restoring ROS-Induced Transcriptional Repression.Nutrients · 2021Article
- Evidence-Based View of Safety and Effectiveness of Prokineticin Receptors Antagonists during Pregnancy.Biomedicines · 2021Article
- Role of Vascular Endothelial Growth Factor (VEGF) in Human Embryo Implantation: Clinical Implications.Biomolecules · 2021Review
- PEG Linker Improves Antitumor Efficacy and Safety of Affibody-Based Drug Conjugates.International journal of molecular sciences · 2021Article
- Tuning the Polymorphism of the Anti-VEGF G-rich V7t1 Aptamer by Covalent Dimeric Constructs.International journal of molecular sciences · 2020Article
- Selection and Characterization of a Novel DNA Aptamer, Apt-07S Specific to Hepatocellular Carcinoma Cells.Drug design, development and therapy · 2020Article
- Integration of multiple computer modeling software programs for characterization of a brain natriuretic peptide sandwich DNA aptamer complex.Journal of molecular recognition : JMR · 2019Article
- Site-specific anchoring aptamer C2NP on DNA origami nanostructures for cancer treatment.RSC advances · 2018Article
- Aptamer Therapeutics in Cancer: Current and Future.Cancers · 2018Review
- Aptamers in the Therapeutics and Diagnostics Pipelines.Theranostics · 2018Review
- SL2B aptamer and folic acid dual-targeting DNA nanostructures for synergic biological effect with chemotherapy to combat colorectal cancer.International journal of nanomedicine · 2017Article
- Aptamers: A promising chemical antibody for cancer therapy.Oncotarget · 2016Review
- Nucleic acid aptamer-guided cancer therapeutics and diagnostics: the next generation of cancer medicine.Theranostics · 2015Review
- Toxicogenomics and cancer susceptibility: advances with next-generation sequencing.Journal of environmental science and health. Part C, Environmental carcinogenesis & ecotoxicology reviews · 2014Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Vascular endothelial growth factor (VEGF) is an angiogenic mitogen involved in promoting tumor angiogenesis inside the body. VEGF is a key protein required for progression of tumor from benign to malignant phenotype. In this study, we investigated the binding affinity of a previously selected 26-mer DNA aptamer sequence (SL(2)-B) against heparin binding domain (HBD) of VEGF(165) protein. The SL(2)-B was first chemically modified by introduction of phosphorothioate linkages (PS-linkages). Subsequently, surface plasmon resonance (SPR) spectroscopy and circular dichroism (CD) were used to determine the binding affinity, specificity and to deduce the conformation of PS-modified SL(2)-B sequence. Finally, antiproliferative activity of the modified SL(2)-B sequence on Hep G2 cancer cells was investigated. Our results demonstrate a marked enhancement in the biostability of the SL(2)-B sequence after PS modification. The modified SL(2)-B sequence also exhibits enhanced antiproliferative activity against Hep G2 cancer cells in hypoxia conditions. In addition, modified SL(2)-B sequence inhibits the expression of Jagged-1 protein, which is one of the ligands to VEGF linked delta/jagged-notch signaling pathway.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.